Seres Therapeutics

Seres Therapeutics reports from an investigator-initiated study with 15 patients that 12 participants achieved clinical improvement of diarrheal symptoms by day 15 without immunosuppressive therapy, five of them complete. By day 43, several patients maintained ongoing responses or remissions without systemic therapy; no serious adverse events associated with SER-155 were reported. Biomarkers of gastrointestinal inflammation and mucosal integrity improved significantly; the company is seeking partners and funding for further studies while its financial position remains strained. » More on de.investing.com

Seres Therapeutics agreed to an amendment to the sale of VOWST to Nestlé Health Science: Nestlé will pay $25 million in two installments in July and October 2026 as compensation for potential sales‑based milestones. Seres also restructured the lease for its Cambridge site, reducing space, rent and operating costs, and posted a new bank guarantee. The company reported cash and cash equivalents of $29.8 million as of March 31, 2026; its stock is trading near the 52‑week low. Seres expects clinical data for SER‑155 later this month. » More on de.investing.com

Seres Therapeutics has suspended investment in the planned phase‑2 study of SER‑155 and reduced its workforce by around 30%, a move that weighed notably on the share price. The company has finalized the study protocol with the FDA but is delaying the start until financing is secured. Cost reductions are intended to extend liquidity into the third quarter of 2026; Seres is now focusing on early‑stage programs and is exploring partnerships to raise capital. Results from a fully recruited, investigator‑initiated study of SER‑155 in immune‑checkpoint‑associated enterocolitis are expected in early Q2 2026. » More on de.investing.com